Capsida Biotherapeutics

Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening disorders.

In the past, nearly all gene therapies have been aimed at treating rare disorders in infants – partially because of tremendous unmet need in those patients but mainly because of the limitations of naturally occurring AAV capsids. At Capsida, we’re not limited by the way things have always been done. We’ve developed a high throughput platform to biologically screen and identify proprietary engineered capsids to significantly improve target specificity and penetration in disease tissues and cells, allowing the use of gene therapy in both rare and common diseases across all ages.

Through intravenous (IV) delivery of a single, engineered capsid, Capsida’s technology can target single or multiple organs simultaneously while limiting exposure to non-targeted organs.

We harness the power of our diverse backgrounds and thoughts to deliver on our purpose. We have a sense of collective responsibility and unity. We approach every challenge with energy and excitement. We remain resilient in the face of adversity because we understand innovative science is not easy. We blend innovation with execution in the pursuit to improve patient lives. We’re not limited by the way things have always been done.

Seize the opportunity to be at the forefront of gene therapy. Capsida is a rapidly growing company based in the heart of the Greater Los Angeles biotech hub. We’re looking for passionate, dedicated colleagues to join us.

BENEFITS

Health Benefits:
• Medical, dental, vision, prescription drug coverage
• Multiple plan options including PPO and HMO
• Employee and dependent coverage is 100% company funded (95% company funded for PPO option)
• Medical insurance waiver benefit if you have other coverage

Financial Benefits:
• Competitive base salary
• Bonus program
• Equity participation
• Life and disability Insurance
• 401k plan

Additional Benefits:
• Paid parental leave
• Competitive PTO, paid holidays and a winter shutdown
• Employee Resource Groups
• Employee Assistance Program
• On-site snacks

1300 Rancho Conejo Blvd. Thousand Oaks CA 91320 US
AWARDS
  • NextGen Class of 2022
  • 2023 Best Places to Work
NEWS
Adeno-associated viruses have long been go-to vectors for gene therapies. How AAVs are improving will be among the cell and gene therapy topics to be covered in Baltimore this week.
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
With more than $600 million on the line, AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics to advance three gene therapy programs for eye diseases.
The American Society of Gene and Cell Therapy annual meeting continues to see companies showcasing promising therapeutics for multiple disease indications.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
The California biotech aspires to be a catalyst for the acceleration of gene therapy across a range of therapeutic areas, beginning with three serious neurodegenerative disease targets.
JOBS
IN THE PRESS